Tyrosine kinase inhibitor-induced severe bullous pemphigoid in a patient with advanced stage of liver cancer: a case report and literature review

Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR2) targeted chemotherapy for solid tumors, has revealed promising efficacy in treating liver cancer in China. Although it has been reported to have a high incidence of inducing hand-foot skin reactions, other skin adverse reactions induced by apatinib are rare. Herein, we report a rare case of apatinib-induced severe bullous dermatosis that was successfully treated with methylprednisolone and summarize the dermatologic toxicities of VEGFR tyrosine kinase inhibitor.